Dear Spiral user, We’re pleased to introduce Helix, https://helix.imperial.ac.uk/ Imperial’s new repository for research datasets. Please use Helix for all future dataset deposits. There is no change to Spiral - continue depositing as usual. For queries, contact the Research Data Management team at rdm-enquiries@imperial.ac.uk. Kind regards, the Spiral Team. The Spiral team
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest
File(s)
OA Location
Author(s)
Al Shaer, Danah
Al Musaimi, Othman
Albericio, Fernando
de la Torre, Beatriz G
Type
Journal Article
Abstract
2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs. 59), the total number of TIDES authorized increased (seven vs. three). Year after year, TIDES are increasingly present in therapy, as imaging agents, theragnostic and constituent moieties of other complex drugs, such as antibody drug conjugates. This means a consolidation of these kinds of drugs in the pharmaceutical arena, paving the way in the coming years for the approval of others for diverse medical indications. Here the TIDES approved in 2019 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.
Date Issued
2020-03-05
Date Acceptance
2020-03-03
Citation
Pharmaceuticals, 2020, 13 (3), pp.1-15
URI
URL
DOI
ISSN
1424-8247
Publisher
MDPI AG
Start Page
1
End Page
15
Journal / Book Title
Pharmaceuticals
Volume
13
Issue
3
Copyright Statement
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
License URL
Identifier
https://www.mdpi.com/1424-8247/13/3/40
Subjects
Science & Technology
Life Sciences & Biomedicine
Chemistry, Medicinal
Pharmacology & Pharmacy
afamelanotide
bremelanotide
DOTATOC
drugs
Ga-68-DOTATOC
enfortumab vedotin
golodirsen
givosiran
polatuzumab vedotin
oligonucleotides
peptides
pharmaceutical market
ANTIBODY-DRUG CONJUGATE
ANTINEOPLASTIC AGENTS
ENFORTUMAB VEDOTIN
HORMONE
AFAMELANOTIDE
GA-68-DOTATOC
MANAGEMENT
DS-8201A
SAFETY
ADC
68Ga-DOTATOC
DOTATOC
afamelanotide
bremelanotide
drugs
enfortumab vedotin
givosiran
golodirsen
oligonucleotides
peptides
pharmaceutical market
polatuzumab vedotin
1115 Pharmacology and Pharmaceutical Sciences
Publication Status
Published
Date Publish Online
2020-03-05